Comparative Pharmacology
Head-to-head clinical analysis: DEMEROL versus OLINVYK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMEROL versus OLINVYK.
DEMEROL vs OLINVYK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is an opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia, sedation, and euphoria. It also has additional weak actions at kappa and delta receptors.
Oliceridine is a G protein-biased μ-opioid receptor agonist. It preferentially activates the G protein pathway (associated with analgesia) over β-arrestin recruitment (associated with opioid-related adverse effects like respiratory depression and gastrointestinal dysfunction).
50-150 mg IM, IV, or SC every 3-4 hours as needed for pain; oral 50-150 mg every 3-4 hours.
Initial adult dose: 1.5 mg intravenously (IV) every 3 to 6 hours as needed. May be titrated in increments of 0.75 mg to 1.5 mg every 3 to 6 hours. Maximum single dose: 4.5 mg. Maximum daily dose: 27 mg.
None Documented
None Documented
2.5-4 hours; prolonged in hepatic impairment (7-11 hours) and elderly.
Terminal elimination half-life is approximately 26–29 hours, supporting once-daily dosing in chronic pain
Renal (90% as metabolites and unchanged drug; ~5% unchanged) and biliary/fecal (minor).
Primarily renal (approximately 90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <5%
Category C
Category C
Opioid Analgesic
Opioid Analgesic